Pediatric Infectious Disease

Register      Login

VOLUME 6 , ISSUE 1 ( January-March, 2024 ) > List of Articles

Original Article

Clinical Profile and Prescription Patterns in Culture-proven Enteric Fever in Children

Divya Priyadharshini, Mobill Clinton, Mathrubootham Sridhar, Vidya Krishna

Keywords : Culture-proven enteric fever, Drug susceptibility in enteric fever, Enteric fever in children, Prescription patterns in enteric fever, Salmonella typhi and paratyphi in Indian children

Citation Information : Priyadharshini D, Clinton M, Sridhar M, Krishna V. Clinical Profile and Prescription Patterns in Culture-proven Enteric Fever in Children. Pediatr Inf Dis 2024; 6 (1):6-9.

DOI: 10.5005/jp-journals-10081-1408

License: CC BY-NC 4.0

Published Online: 16-03-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Aim: We aimed to study the clinical profile of enteric fever in children at an urban tertiary care children's hospital in South India. Materials and methods: We carried out a retrospective study of culture-proven enteric fever in children aged 0–18 years between January 2018 and March 2023. We included 128 children in total; 109 inpatients (85.2%) and 19 outpatients (14.8%). Results: Enteric fever accounted for 4.9% of nonrespiratory febrile admissions (n = 2,204). A total of 98 (76.5%) had Salmonella typhi (S. typhi), while 30 (23.5%) had Salmonella paratyphi (S. paratyphi) A in their blood. Leukopenia occurred in 28 (21.8%) patients. The average inpatient fever defervescence time was 4.62 days (range: 1–28 days). A total of 26 children (20.3%) experienced fever defervescence after 5 days. The mean C-reactive protein (CRP) was 58.2 mg/dL in the group with fever defervescence in <5 days and 63.3 mg/dL for >5 days (p = 0.540). Single antibiotic was used in only 25 children (19.5%). Mean fever defervescence time was 4.8 days in the single antibiotic group and 4.5 days in the combination group (p = 0.47), and in typhoid vs paratyphoid, it was 4.8 vs 3.3 days (p = 0.04). Conclusion: Salmonella paratyphi (S. paratyphi) caused 23.5% of culture-proven enteric fever cases. Most cases had normal leukocyte counts, eosinopenia, and elevated CRP. CRP does not predict fever defervescence. Fever typically resolved in 4–5 days, with paratyphoid fever resolving earlier. Combination therapy was used in over two-thirds of cases. Clinical significance: Salmonella paratyphi (S. paratyphi) is a significant cause of enteric fever in children. There seems to be no clear benefit for combination therapy from our small retrospective data, but study limitations preclude drawing accurate conclusions. Future areas of research interest will include an effective vaccine for paratyphoid fever and a randomized clinical trial on single vs combination therapy in enteric fever.

PDF Share
  1. Cao Y, Karthikeyan AS, Ramanujam K, et al. Geographic pattern of typhoid fever in India: a model-based estimate of cohort and surveillance data. J Infect Dis 2021;224(224 Suppl 5):S475–S483. DOI: 10.1093/infdis/jiab187
  2. John J, Bavdekar A, Rongsen-Chandola T, et al. Burden of typhoid and paratyphoid fever in India. N Engl J Med 2023;388(16):1491–1500. DOI: 10.1056/NEJMoa2209449
  3. Qamar FN, Yousafzai MT, Dehraj IF, et al. Antimicrobial resistance in typhoidal Salmonella: surveillance for enteric fever in Asia project, 2016-2019. Clin Infect Dis 2020;71(Suppl 3): S276–S284. DOI: 10.1093/cid/ciaa1323
  4. Parry CM, Qamar FN, Rijal S, et al. What should we be recommending for the treatment of enteric fever? Open Forum Infect Dis 2023;10(Suppl 1):S26–S31. DOI: 10.1093/ofid/ofad179
  5. Walia M, Gaind R, Mehta R, et al. Current perspectives of enteric fever: a hospital-based study from India. Ann Trop Paediatr 2005;25(3): 161–174. DOI: 10.1179/146532805X58085
  6. Behera JR, Rup AR, Dash AK, et al. Clinical and laboratory profile of enteric fever in children from a tertiary care centre in Odisha, Eastern India. Cureus 2021;13(1):e12826. DOI: 10.7759/cureus.12826
  7. Kheng C, Meas V, Pen S, et al. Salmonella typhi and paratyphi A infections in Cambodian children, 2012-2016. Int J Infect Dis 2020;97:334–336. DOI: 10.1016/j.ijid.2020.06.054
  8. Saha S, Sayeed KMI, Saha S, et al. Hospitalization of pediatric enteric fever cases, Dhaka, Bangladesh, 2017-2019: incidence and risk factors. Clin Infect Dis 2020;71(Suppl 3):S196–S204. DOI: 10.1093/cid/ciaa1356
  9. Fazaludeen Koya S, Hasan Farooqui H, Mehta A, et al. Quantifying antibiotic use in typhoid fever in India: a cross-sectional analysis of private sector medical audit data, 2013-2015. BMJ Open 2022;12(10):e062401. DOI: 10.1136/bmjopen-2022-062401
  10. Hughes M, Appiah G, Watkins LF. Typhoid and paratyphoid fever. (CDC), Centers for Disease Control and Prevention, Jeffrey B Nemhauser (eds), CDC Yellow Book 2024.
  11. Zmora N, Shrestha S, Neuberger A, et al. Open label comparative trial of mono versus dual antibiotic therapy for typhoid fever in adults. PLoS Negl Trop Dis 2018;12(4): e0006380. DOI: 10.1371/journal.pntd.0006380
  12. Giri A, Karkey A, Dongol S, et al. Azithromycin and cefixime combination versus azithromycin alone for the outpatient treatment of clinically suspected or confirmed uncomplicated typhoid fever in South Asia: a randomized controlled trial protocol. Wellcome Open Res 2021;6:207. DOI: 10.12688/wellcomeopenres.16801.2
  13. Ganesh R, Janakiraman L, Vasanthi T, et al. Profile of typhoid fever in children from a tertiary care hospital in Chennai-South India. Indian J Pediatr 2010;77(10):1089–1092. DOI: 10.1007/s12098-010-0196-9
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.